Application No.: Not Yet Assigned

Docket No.: 1912-0308PUS1


REMARKS

The Abstract of the Disclosure is hereby submitted on a separate sheet of paper. The claims have been amended to cancel claims 34-49. No new matter has been introduced. Claims 1-33 are pending in this application. Claims 34-49 have been canceled.

Conclusion

Entry of the above amendments is earnestly solicited. An early and favorable first action on the merits is earnestly solicited.

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact Mary Anne Armstrong (Reg. No. 40,069) at the telephone number of the undersigned below, to conduct an interview in an effort to expedite prosecution in connection with the present application.



Docket No.: 1912-0308PUS1

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37.C.F.R. §§1.16 or 1.14; particularly, extension of time fees.

Dated: April 22, 2005

Respectfully submitted,

Attorney for Applicant

MAA/clb

By Yna www.
Mary Anne Armstrong
Registration No.: 40,069
BIRCH, STEWART, KOLASCH & BIRCH, LLP
8110 Gatehouse Rd
Suite 100 East
P.O. Box 747
Falls Church, Virginia 22040-0747
(703) 205-8000

Application No.: Not Yet Assigned Docket No.: 1912-0308PUS1

ABSTRACT OF THE INVENTION

The present invention relates to a method to stimulate reversal of a diabetic state in a

patient; a method to prevent autoimmune destruction of new insulin-producing cells (pancreatic

beta-cells) in a patient; a method to promote survival of the newly regenerated insulin-producing

cells (pancreatic beta-cells); and an in vivo method for the induction of islet cell neogenesis and

new islet formation and the prevention of autoimmune destruction of said new cells.